Research Examines Possible Connection Between COVID-19 Vaccines and Post-Vaccination Syndrome
A study conducted by Yale University investigates the symptoms linked to a condition that certain individuals claim to experience following vaccination.
A recent investigation has explored the potential connection between COVID-19 vaccines and a condition known as 'post-vaccination syndrome' (PVS), revealing that some individuals might endure enduring symptoms following vaccination.
Research conducted by Yale University illuminates a variety of symptoms reported by participants, such as exercise intolerance, severe fatigue, numbness, brain fog, insomnia, palpitations, tinnitus, dizziness, muscle pain, and alterations in immune function.
These symptoms typically manifest within one to two days after vaccination and may worsen over time, enduring long after the initial immunization.
Since the COVID-19 pandemic began, many people worldwide have reported possible long-term negative effects linked to COVID-19 vaccines, even though these vaccines play a significant role in preventing serious illness and death from the virus.
Few studies have examined the long-term effects of vaccination, especially concerning PVS.
Dr. Akiko Iwasaki, an immunologist heading the research at Yale, underscored the necessity for further investigation into this condition, pointing out that individuals affected by PVS often feel neglected due to its absence of formal acknowledgment in the medical field.
The research drew data from Yale's Listen to Immune, Symptom, and Treatment Experiences Now (LISTEN) Study, which included 42 participants experiencing PVS symptoms and a control group of 22 individuals without such symptoms.
The findings indicated differences in immune profiles between those with PVS and the controls, with similarities to the profiles of patients suffering from long COVID.
Significantly, a reactivation of the Epstein-Barr virus was identified among PVS participants; this virus can lie dormant and is linked to various conditions, including mononucleosis and multiple sclerosis.
The researchers acknowledged the preliminary nature of their results and called for more comprehensive studies to determine the prevalence and mechanisms of PVS.
They expressed optimism that ongoing research could lead to better diagnostics and treatment options for those experiencing this syndrome.
A deeper understanding could potentially inform future vaccine designs aimed at minimizing adverse effects, diagnosing PVS, and developing targeted treatment strategies.
Research conducted by Yale University illuminates a variety of symptoms reported by participants, such as exercise intolerance, severe fatigue, numbness, brain fog, insomnia, palpitations, tinnitus, dizziness, muscle pain, and alterations in immune function.
These symptoms typically manifest within one to two days after vaccination and may worsen over time, enduring long after the initial immunization.
Since the COVID-19 pandemic began, many people worldwide have reported possible long-term negative effects linked to COVID-19 vaccines, even though these vaccines play a significant role in preventing serious illness and death from the virus.
Few studies have examined the long-term effects of vaccination, especially concerning PVS.
Dr. Akiko Iwasaki, an immunologist heading the research at Yale, underscored the necessity for further investigation into this condition, pointing out that individuals affected by PVS often feel neglected due to its absence of formal acknowledgment in the medical field.
The research drew data from Yale's Listen to Immune, Symptom, and Treatment Experiences Now (LISTEN) Study, which included 42 participants experiencing PVS symptoms and a control group of 22 individuals without such symptoms.
The findings indicated differences in immune profiles between those with PVS and the controls, with similarities to the profiles of patients suffering from long COVID.
Significantly, a reactivation of the Epstein-Barr virus was identified among PVS participants; this virus can lie dormant and is linked to various conditions, including mononucleosis and multiple sclerosis.
The researchers acknowledged the preliminary nature of their results and called for more comprehensive studies to determine the prevalence and mechanisms of PVS.
They expressed optimism that ongoing research could lead to better diagnostics and treatment options for those experiencing this syndrome.
A deeper understanding could potentially inform future vaccine designs aimed at minimizing adverse effects, diagnosing PVS, and developing targeted treatment strategies.
Comments
Oh ya 1 year ago
But but but it is, safe and affective. If you took this clot shot you best start doing some research on your own and not listen to the main steam media as it was them that conned you into taking it in the 1st place. Start by Google search of FLCCC. Best of luck, you will need it.